US FDA Reassures ALS Patients In Final Development Guidance

 
• By Derrick Gingery

ALS advocates succeed in getting the FDA to soften its stance on use of randomized, placebo-controlled trials for drug development; final guidance also encourages patient-reported outcomes.

nerve cells, concept for neurodegenerative and neurological disease
The FDA encouraged development of endpoints that measure function in daily living in final ALS drug development guidance. • Source: Shutterstock

More from R&D

More from Pink Sheet